{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:41:02Z","timestamp":1792802462787,"version":"4.5.0"},"reference-count":118,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology Young Investigator Award","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dana-Farber Harvard Cancer Center Timely Opportunity Award","id":[{"id":"https:\/\/ror.org\/03pvyf116","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Program in Cancer Outcomes Research Training","award":["5R25CA 092203-04"],"award-info":[{"award-number":["5R25CA 092203-04"]}]},{"name":"Department of Medicine"},{"DOI":"10.13039\/100005615","name":"Beth Israel Deaconess Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005615","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Investigator Training Program: Beth Israel Deaconess Medical Center\u2013Harvard\/MIT Health Sciences and Technology"},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose.<\/jats:title>\n                    <jats:p>Potentially debilitating, osteonecrosis of the jaw (ONJ) is an emerging complication of bisphosphonates. However, its effect on quality of life (QoL) is unknown. We determined the ONJ-related QoL decline in a cancer patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods.<\/jats:title>\n                    <jats:p>Thirty-four cancer patients with bisphosphonate-associated ONJ completed a telephone survey (October 2007 through May 2008). The Oral Health Impact Profile 14 (OHIP) retrospectively assessed participant oral health\u2013related QoL before and after ONJ. Standardized ONJ descriptions were developed in a multidisciplinary, iterative process and were evaluated with three frequently used preference-based QoL measurement methods on a 0 (death) to 1 (perfect health) scale: Visual Analogue Scale (VAS), Time Trade-Off (TTO), and EQ-5D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>ONJ significantly (p &amp;lt; .001) increased OHIP scores (worse QoL) for additive (3.56\u201316.53) and weighted (7.0\u201317.5) methods. Seven individual OHIP items significantly increased (Bonferroni correction p &amp;lt; .0035): pain, eating discomfort, self-consciousness, unsatisfactory diet, interrupted meals, irritability, and decreased life satisfaction. Mean preference-based QoL values significantly decreased (p &amp;lt; .001) with worsening ONJ stage (VAS, TTO, and EQ-5D): no ONJ (0.76, 0.86, 0.82), ONJ stage 1 (0.69, 0.82, 0.78), ONJ stage 2 (0.51, 0.67, 0.55), and ONJ stage 3 (0.37, 0.61, 0.32). As ONJ worsened, EQ-5D domain scores significantly increased (p &amp;lt; .001). Pain\/discomfort and anxiety\/depression contributed most to declining QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>ONJ significantly affects QoL, a detriment that increases with worsening ONJ. QoL impairments for ONJ stages 2 and 3 are similar to other treatment side effects that influence decision-making. Bisphosphonate-associated ONJ QoL is an important consideration for patients, clinicians, and policy makers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2010-0183","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T00:10:22Z","timestamp":1294359022000},"page":"121-132","source":"Crossref","is-referenced-by-count":139,"title":["Quality of Life Implications of Bisphosphonate-Associated Osteonecrosis of the Jaw"],"prefix":"10.1093","volume":"16","author":[{"given":"Rebecca Anne","family":"Miksad","sequence":"first","affiliation":[{"name":"a Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA;"},{"name":"b Harvard Medical School, Boston, Massachusetts, USA;"},{"name":"c Institute for Technology Assessment, Boston, Massachusetts, USA;"},{"name":"d Massachusetts General Hospital, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chi","family":"Lai","sequence":"additional","affiliation":[{"name":"a Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA;"},{"name":"c Institute for Technology Assessment, Boston, Massachusetts, USA;"},{"name":"d Massachusetts General Hospital, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Benton","family":"Dodson","sequence":"additional","affiliation":[{"name":"d Massachusetts General Hospital, Boston, Massachusetts, USA;"},{"name":"e Harvard School of Dental Medicine, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook-Bin","family":"Woo","sequence":"additional","affiliation":[{"name":"e Harvard School of Dental Medicine, Boston, Massachusetts, USA;"},{"name":"f Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel Simon","family":"Treister","sequence":"additional","affiliation":[{"name":"e Harvard School of Dental Medicine, Boston, Massachusetts, USA;"},{"name":"f Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omosalewa","family":"Akinyemi","sequence":"additional","affiliation":[{"name":"c Institute for Technology Assessment, Boston, Massachusetts, USA;"},{"name":"d Massachusetts General Hospital, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Bihrle","sequence":"additional","affiliation":[{"name":"a Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA;"},{"name":"c Institute for Technology Assessment, Boston, Massachusetts, USA;"},{"name":"d Massachusetts General Hospital, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Maytal","sequence":"additional","affiliation":[{"name":"d Massachusetts General Hospital, Boston, Massachusetts, USA;"},{"name":"e Harvard School of Dental Medicine, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"August","sequence":"additional","affiliation":[{"name":"d Massachusetts General Hospital, Boston, Massachusetts, USA;"},{"name":"e Harvard School of Dental Medicine, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Scott","family":"Gazelle","sequence":"additional","affiliation":[{"name":"b Harvard Medical School, Boston, Massachusetts, USA;"},{"name":"c Institute for Technology Assessment, Boston, Massachusetts, USA;"},{"name":"d Massachusetts General Hospital, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Shannon","family":"Swan","sequence":"additional","affiliation":[{"name":"b Harvard Medical School, Boston, Massachusetts, USA;"},{"name":"c Institute for Technology Assessment, Boston, Massachusetts, USA;"},{"name":"d Massachusetts General Hospital, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,1,6]]},"reference":[{"issue":"2","key":"2021122303221238000_B1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tripleo.2006.12.004","article-title":"Bisphosphonates and osteonecrosis of the jaws: science and rationale","volume":"104","author":"Gutta","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"6","key":"2021122303221238000_B2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0714.2007.00540.x","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review","volume":"36","author":"Hewitt","year":"2007","journal-title":"J Oral Pathol Med"},{"issue":"5","key":"2021122303221238000_B3","first-page":"417","article-title":"A review of bisphosphonate-associated osteonecrosis of the jaws and its management","volume":"73","author":"Lam","year":"2007","journal-title":"J Can Dent Assoc"},{"issue":"8","key":"2021122303221238000_B4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/j.0022-0337.2008.72.8.tb04568.x","article-title":"Bisphosphonates and osteonecrosis of the jaws","volume":"72","author":"Mariotti","year":"2008","journal-title":"J Dent Educ"},{"issue":"6","key":"2021122303221238000_B5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","article-title":"Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment","volume":"7","author":"Migliorati","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"2021122303221238000_B6","first-page":"96","article-title":"Bisphosphonate-related osteonecrosis of the jaws","volume":"29","author":"Ruggiero","year":"2008","journal-title":"Compend Contin Educ Dent"},{"issue":"4","key":"2021122303221238000_B7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","article-title":"Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management","volume":"102","author":"Ruggiero","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"10","key":"2021122303221238000_B8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"issue":"13","key":"2021122303221238000_B9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jnci\/djm025","article-title":"Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis","volume":"99","author":"Wilkinson","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122303221238000_B10"},{"key":"2021122303221238000_B11"},{"issue":"4","key":"2021122303221238000_B12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2141.2007.06730.x","article-title":"Survey of members of myeloma U.K. on biphosphonates-associated jaw osteonecrosis","volume":"139","author":"Barker","year":"2007","journal-title":"Br J Haematol"},{"issue":"6","key":"2021122303221238000_B13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2021122303221238000_B14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"2021122303221238000_B15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"2021122303221238000_B16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"issue":"9","key":"2021122303221238000_B17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol"},{"issue":"5","key":"2021122303221238000_B18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/02841860601185917","article-title":"Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis","volume":"46","author":"Ortega","year":"2007","journal-title":"Acta Oncol"},{"issue":"3","key":"2021122303221238000_B19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","article-title":"Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies","volume":"112","author":"Fehm","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2021122303221238000_B20","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","article-title":"A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","volume":"18","author":"Jadu","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"2021122303221238000_B21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00520-006-0120-z","article-title":"Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis","volume":"15","author":"Walter","year":"2007","journal-title":"Support Care Cancer"},{"issue":"3","key":"2021122303221238000_B22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"2021122303221238000_B23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1634\/theoncologist.2007-0159","article-title":"Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study","volume":"13","author":"Ibrahim","year":"2008","journal-title":"The Oncologist"},{"issue":"3","key":"2021122303221238000_B24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4158\/EP.13.3.232","article-title":"Bisphosphonates and osteonecrosis of the jaw: a retrospective study","volume":"13","author":"Murad","year":"2007","journal-title":"Endocr Pract"},{"issue":"5 Suppl","key":"2021122303221238000_B25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.joms.2008.12.004","article-title":"Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Dodson","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"issue":"12","key":"2021122303221238000_B26","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2006-07-033571","article-title":"Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone","volume":"108","author":"Tosi","year":"2006","journal-title":"Blood"},{"key":"2021122303221238000_B27","volume-title":"Clinical, Pharmacological, and Biological Issues in ONJ","author":"Barasch","year":"2010"},{"key":"2021122303221238000_B28","volume-title":"Findings of the CONDOR Case-Control Study of ONJ","author":"Curro","year":"2010"},{"issue":"12","key":"2021122303221238000_B29","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3899\/jrheum.090455","article-title":"Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients","volume":"36","author":"Favia","year":"2009","journal-title":"J Rheumatol"},{"key":"2021122303221238000_B30","volume-title":"Actonel Label Prescribing Information","author":"FDA","year":"2009"},{"key":"2021122303221238000_B31","volume-title":"Boniva Label Prescribing Information","author":"FDA","year":"2010"},{"key":"2021122303221238000_B32","volume-title":"Fosamax Label Prescribing Information","author":"FDA","year":"2010"},{"key":"2021122303221238000_B33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3121\/cmr.8.1.42-b","article-title":"PS1\u201331: osteonecrosis of the jaw in two dental PBRN health plans","volume":"8","author":"Fellows","year":"2010","journal-title":"Clin Med Res"},{"key":"2021122303221238000_B34","volume-title":"Design of the CONDOR Case-Control Study of ONJ","author":"Hujoel","year":"2010"},{"issue":"2","key":"2021122303221238000_B35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303221238000_B36","volume-title":"Prescription Drug User Fee Act (PDUFA) IV Drug Safety Five-Year Plan 2008\u20132012","author":"FDA"},{"issue":"5","key":"2021122303221238000_B37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1634\/theoncologist.2007-0200","article-title":"Use of intravenous bisphosphonates in older women with breast cancer","volume":"13","author":"Giordano","year":"2008","journal-title":"The Oncologist"},{"key":"2021122303221238000_B38","volume-title":"Product Sales","author":"Novartis"},{"key":"2021122303221238000_B39","volume-title":"Phase III Randomized Study of Adjuvant Zoledronate Versus Clodronate Versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast"},{"issue":"5","key":"2021122303221238000_B40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"The Oncologist"},{"key":"2021122303221238000_B41","volume-title":"Zolandronic acid protective effect on bone loss in postmenopausal women switched from tamoxifen to letrozole in the treatment of early breast cancer [abstract 1153]","author":"Safra","year":"2008"},{"issue":"7","key":"2021122303221238000_B42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"29","key":"2021122303221238000_B43","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2021122303221238000_B44","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"issue":"6","key":"2021122303221238000_B45","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","article-title":"Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial","volume":"90","author":"Fuleihan Gel","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2021122303221238000_B46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"issue":"16","key":"2021122303221238000_B47","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"2021122303221238000_B48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"J Clin Periodontol"},{"issue":"10","key":"2021122303221238000_B49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1600-0714.2005.00351.x","article-title":"Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report","volume":"34","author":"Merigo","year":"2005","journal-title":"J Oral Pathol Med"},{"issue":"9","key":"2021122303221238000_B50","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1200\/JCO.2005.01.7756","article-title":"Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy","volume":"24","author":"Mignogna","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021122303221238000_B51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2141.2005.05382.x","article-title":"Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma","volume":"128","author":"Vannucchi","year":"2005","journal-title":"Br J Haematol"},{"issue":"12","key":"2021122303221238000_B52","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.joms.2007.04.011","article-title":"Baseline characteristics and treatment preferences of oral surgery patients","volume":"65","author":"Atchison","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"2021122303221238000_B53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1752-7325.2006.tb04077.x","article-title":"Preferences for oral health states in a US community-dwelling functionally impaired older adult population: 2000\u20132001","volume":"66","author":"Thierer","year":"2006","journal-title":"J Public Health Dent"},{"issue":"5","key":"2021122303221238000_B54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1875-595X.2005.tb00328.x","article-title":"The shortened dental arch\u2013an assessment of patients' dental health state utility values","volume":"55","author":"Nassani","year":"2005","journal-title":"Int Dent J"},{"issue":"6","key":"2021122303221238000_B55","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1259\/dmfr\/15454473","article-title":"Preferences for oral health states: effect on prescribing periapical radiographs","volume":"32","author":"Mileman","year":"2003","journal-title":"Dentomaxillofac Radiol"},{"issue":"2","key":"2021122303221238000_B56","first-page":"124","article-title":"The relevance of health state utilities to lower third molar surgery","volume":"45","author":"Brickley","year":"1995","journal-title":"Int Dent J"},{"issue":"10","key":"2021122303221238000_B57","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ijom.2006.07.017","article-title":"Patients' perceived health status following primary surgery for oral and oropharyngeal cancer","volume":"35","author":"Rogers","year":"2006","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"2","key":"2021122303221238000_B58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00019053-199915020-00006","article-title":"Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS","volume":"15","author":"Ackerman","year":"1999","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"2021122303221238000_B59","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1524-4733.2007.00302.x","article-title":"An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom","volume":"11","author":"Brown","year":"2008","journal-title":"Value Health"},{"key":"2021122303221238000_B60","article-title":"The Cost-Effectiveness Analysis Registry","volume-title":"IfCRaHPS, Tufts Medical Center","author":"Center for the Evaluation of Value and Risk in Health"},{"issue":"6","key":"2021122303221238000_B61","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"issue":"17","key":"2021122303221238000_B62","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"21","key":"2021122303221238000_B63","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021122303221238000_B64","first-page":"1391","article-title":"Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw","volume":"35","author":"Khan","year":"2008","journal-title":"J Rheumatol"},{"issue":"5 Suppl","key":"2021122303221238000_B65","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"issue":"7","key":"2021122303221238000_B66","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdl093","article-title":"Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases","volume":"17","author":"Botteman","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"2021122303221238000_B67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.2000.18.1.72","article-title":"Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"issue":"35","key":"2021122303221238000_B68","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021122303221238000_B69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"15 suppl","key":"2021122303221238000_B70","article-title":"Quality of life implications of osteonecrosis of the jaw in cancer patients: a pilot study","volume":"26","author":"Miksad","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122303221238000_B71","first-page":"106","volume-title":"Decision Making in Health and Medicine: Integrating Evidence and Values","author":"Hunink","year":"2001"},{"key":"2021122303221238000_B72","first-page":"191","volume-title":"Quality of Life and Pharmacoeconomics in Clinical Trials","author":"Kind","year":"1996","edition":"Second Edition"},{"issue":"4","key":"2021122303221238000_B73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/02729890122062622","article-title":"Visual analog scales: do they have a role in the measurement of preferences for health states?","volume":"21","author":"Torrance","year":"2001","journal-title":"Med Decis Making"},{"issue":"2","key":"2021122303221238000_B74","first-page":"118","article-title":"A utility maximization model for evaluation of health care programs","volume":"7","author":"Torrance","year":"1972","journal-title":"Health Serv Res"},{"key":"2021122303221238000_B75","article-title":"Guide to Design and Development of Health-State Utility Instrumentation","volume-title":"McMaster University CHEPA Working Paper Series","author":"Furlong","year":"1990"},{"key":"2021122303221238000_B76","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005","edition":"Third Edition"},{"issue":"5","key":"2021122303221238000_B77","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0895-4356(89)90136-4","article-title":"Methodology for measuring health-state preferences\u2013II: Scaling methods","volume":"42","author":"Froberg","year":"1989","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2021122303221238000_B78","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0277-9536(97)00099-3","article-title":"The comparability and reliability of five health-state valuation methods","volume":"45","author":"Krabbe","year":"1997","journal-title":"Soc Sci Med"},{"key":"2021122303221238000_B79","volume-title":"Calculating the U.S. Population-based EQ-5D Index Score","year":"2005"},{"issue":"3","key":"2021122303221238000_B80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"issue":"4","key":"2021122303221238000_B81","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1600-0528.1997.tb00941.x","article-title":"Derivation and validation of a short-form oral health impact profile","volume":"25","author":"Slade","year":"1997","journal-title":"Community Dent Oral Epidemiol"},{"issue":"2","key":"2021122303221238000_B82","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1034\/j.1600-0528.2003.00051.x","article-title":"Validity of two oral health-related quality of life measures","volume":"31","author":"Robinson","year":"2003","journal-title":"Community Dent Oral Epidemiol"},{"issue":"3","key":"2021122303221238000_B83","first-page":"133","article-title":"Do item weights matter? An assessment using the oral health impact profile","volume":"14","author":"Allen","year":"1997","journal-title":"Community Dent Health"},{"issue":"4","key":"2021122303221238000_B84","first-page":"306","article-title":"Reliability and validity of two oral health related quality of life measures in Myanmar adolescents","volume":"21","author":"Soe","year":"2004","journal-title":"Community Dent Health"},{"issue":"1","key":"2021122303221238000_B85","first-page":"3","article-title":"Measuring oral health: a conceptual framework","volume":"5","author":"Locker","year":"1988","journal-title":"Community Dent Health"},{"issue":"5","key":"2021122303221238000_B86","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1600-0528.2006.00285.x","article-title":"Utility of two oral health-related quality-of-life measures in patients with xerostomia","volume":"34","author":"Baker","year":"2006","journal-title":"Community Dent Oral Epidemiol"},{"key":"2021122303221238000_B87","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/oso\/9780195108248.003.0004","volume-title":"Cost Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"issue":"4","key":"2021122303221238000_B88","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00148365-200504040-00004","article-title":"What value health?: A review of health state values used in early technology assessments for NICE","volume":"4","author":"Stein","year":"2005","journal-title":"Appl Health Econ Health Policy"},{"key":"2021122303221238000_B89","first-page":"253","volume-title":"Quality of Life and Pharmacoeconomics in Clinical Trials","author":"Bennett","year":"1996","edition":"Second Edition"},{"issue":"2","key":"2021122303221238000_B90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00019053-200017020-00004","article-title":"Valuing health-related quality of life. A review of health state valuation techniques","volume":"17","author":"Green","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"2021122303221238000_B91","volume-title":"The Role of Bisphosphonate Therapy in Multiple Myeloma Patients: A perspective on Osteonecrosis of the Jaw and Quality of Life","author":"Akbari","year":"2008"},{"issue":"15","key":"2021122303221238000_B92","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"17","key":"2021122303221238000_B93","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2003.03.052","article-title":"Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival","volume":"21","author":"Woodward","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021122303221238000_B94","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0272989X9701700303","article-title":"Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments","volume":"17","author":"Fryback","year":"1997","journal-title":"Med Decis Making"},{"issue":"5","key":"2021122303221238000_B95","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jts.20053","article-title":"Participant reactions to survey research in the general population after terrorist attacks","volume":"18","author":"Galea","year":"2005","journal-title":"J Trauma Stress"},{"key":"2021122303221238000_B96","volume-title":"Copyright 2002\u20132003 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc","author":"SAS software, Version 9.1 of the SAS System for Windows"},{"issue":"8","key":"2021122303221238000_B97","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"12","key":"2021122303221238000_B98","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s001980170015","article-title":"Impact of hip and vertebral fractures on quality-adjusted life years","volume":"12","author":"Tosteson","year":"2001","journal-title":"Osteoporos Int"},{"issue":"4","key":"2021122303221238000_B99","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.mlr.0000156862.33341.45","article-title":"Utilities for prostate cancer health states in men aged 60 and older","volume":"43","author":"Stewart","year":"2005","journal-title":"Med Care"},{"issue":"4","key":"2021122303221238000_B100","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.urology.2007.12.016","article-title":"Complications of open radical retropubic prostatectomy in potential candidates for active monitoring","volume":"72","author":"Loeb","year":"2008","journal-title":"Urology"},{"issue":"19","key":"2021122303221238000_B101","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/jnci\/92.19.1582","article-title":"Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study","volume":"92","author":"Potosky","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122303221238000_B102","volume-title":"The Standards for Educational and Psychological Testing","year":"1999","edition":"Second Edition"},{"key":"2021122303221238000_B103","volume-title":"Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [abstract 2048]","author":"Solomayer","year":"2008"},{"key":"2021122303221238000_B104","volume-title":"The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response exploratory evidence for direct anti-tumor activity in breast cancer [abstract 5101]","author":"Winter","year":"2008"},{"issue":"12","key":"2021122303221238000_B105","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.14219\/jada.archive.2008.0110","article-title":"Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs","volume":"139","author":"Edwards","year":"2008","journal-title":"J Am Dent Assoc"},{"key":"2021122303221238000_B106","volume-title":"Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone"},{"issue":"4","key":"2021122303221238000_B107","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"2021122303221238000_B108","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"issue":"34","key":"2021122303221238000_B109","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021122303221238000_B110","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"2021122303221238000_B111","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"2021122303221238000_B112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"2021122303221238000_B113","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2021122303221238000_B114","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/jwh.2008.0959","article-title":"Quality of life and self-esteem of long-term survivors of invasive and noninvasive cervical cancer","volume":"18","author":"Bartoces","year":"2009","journal-title":"J Womens Health (Larchmt)"},{"issue":"11","key":"2021122303221238000_B115","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1634\/theoncologist.2009-0115","article-title":"Bisphosphonates and time to osteonecrosis development","volume":"14","author":"Palaska","year":"2009","journal-title":"The Oncologist"},{"issue":"18","key":"2021122303221238000_B116","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2000.18.18.3302","article-title":"Systematic overview of cost-utility assessments in oncology","volume":"18","author":"Earle","year":"2000","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021122303221238000_B117","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s11136-007-9202-8","article-title":"Health related quality of life in different states of breast cancer","volume":"16","author":"Lidgren","year":"2007","journal-title":"Qual Life Res"},{"issue":"6","key":"2021122303221238000_B118","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0183","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/1\/121\/41853304\/oncolo_16_1_121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/1\/121\/41853304\/oncolo_16_1_121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T16:17:59Z","timestamp":1712074679000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/1\/121\/6400655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,6]]},"published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0183","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,1,1]]},"published":{"date-parts":[[2011,1,1]]}}}